Healthcare Equipment and Supplies
Company Overview of Novocure Ltd.
Novocure Ltd. offers research and development of cancer treatment devices. The company develops NovoTTF-100A, a portable non-invasive investigational device for cancer treatment using tumor treating fields; and NovoTAL System, a workstation-based propriety software tool that uses MRI head morphology, tumor size and location measurements, and tissue dielectric properties to optimize TTField distribution and intensity in the target tumor. It offers devices for continuous home use by patients. Novocure Ltd. was founded in 2000 and is based in Saint Helier, Channel Islands with additional offices in Portsmouth, New Hampshire and Haifa, Israel.
Le Masurier House
La Rue Le Masurier
Saint Helier, JE2 4YE
Founded in 2000
Key Executives for Novocure Ltd.
Chief Executive Officer and Director
Vice Chairman and Chairman of The Global Commercialization Team
Compensation as of Fiscal Year 2014.
Novocure Ltd. Key Developments
Novocure Announces Interim Analysis of Phase III Trial in Newly Diagnosed Glioblastoma
Dec 1 14
Novocure announced that the interim analysis of the EF-14 Phase III trial of Tumor Treating Fields (TTFields) therapy in patients with newly diagnosed glioblastoma will be presented on December 2, 2014 at the Japan Society for Neuro-Oncology (JSNO) 2014 Annual Meeting in Maihama, Chiba, Japan. The pre-specified, EF-14 interim analysis encompassed the first 315 patients, representing 50% of the targeted study population. The data show that: Patients treated with TTFields together with temozolomide demonstrated a significant increase in progression-free survival (PFS) compared to temozolomide alone (median PFS of 7.1 months compared to 4.0 months, respectively, hazard ratio=0.63, p=0.001). Patients treated with TTFields together with temozolomide demonstrated a significant increase in overall survival (OS) compared to temozolomide alone (median OS of 19.6 months compared to 16.6 months, respectively, hazard ratio=0.75, p=0.034). The percentage of patients alive at 2 years in the TTFields together with temozolomide arm was 43% compared to 29% in the temozolomide alone arm, a 48% increase in the 2-year survival compared to temozolomide alone.
Novocure Announces Presentation of New Data of Pivotal Phase III EF-14 Study
Nov 11 14
Novocure announced that the pre-specified interim analysis of the pivotal phase III EF-14 study, a prospective, multi-center trial of Tumor Treating Fields (TTFields) together with temozolomide compared to temozolomide alone in patients with newly diagnosed glioblastoma, will be presented as a late breaking oral presentation at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, November 13 to 16, in Miami, Florida. In addition to the EF-14 interim analysis presentation, an additional 10 preclinical and clinical abstracts from leading academic institutions describing the new aspects of TTFields therapy will be presented at the meeting.
Novocure Ltd. Announces Publication of Four Articles on NovoTTF Therapy
Oct 29 14
Novocure announced the publication of four articles on NovoTTF Therapy in a Seminars in Oncology supplement. The supplement includes an article describing the findings from Novocure's U.S. commercial Patient Registry Dataset (PRiDe) and includes data from every recurrent glioblastoma patient treated with the NovoTTF-100A System from October 2011 through November 2013 at 91 oncology centers in the United States (n=457). Analyses of the PRiDe data showed that recurrent glioblastoma patients treated with the NovoTTF-100A System in the real-world setting at first or second recurrence had a longer median overall survival (OS) compared to patients treated at their third or subsequent recurrences (median OS of 20.0 months and 8.5 months compared to 4.9 months, respectively, p<0.0001). Another PRiDe analysis showed that the median overall survival of bevacizumab-naive recurrent glioblastoma patients treated with the NovoTTF-100A System was significantly longer than the median OS of recurrent glioblastoma patients treated with bevacizumab prior to treatment with the NovoTTF-100A System (median OS 13.4 months vs. 7.2 months, respectively, p=0.0001). The NovoTTF Therapy supplement is comprised of the following articles: Clinical Experience with NovoTTF-100A System for Glioblastoma: the Patient Registry Dataset (PRiDe). Maciej M. Mrugala, Herbert H. Engelhard, David Dinh Tran, Yvonne Kew, Robert Cavaliere, John L. Villano, Daniela Annenelie Bota, Jeremy Rudnick, Ashley Love Sumrall, Jay-Jiguang Zhu, Nicholas Butowski. Glioblastoma (GBM) is the most common form of primary brain cancer with approximately 10,000 patients diagnosed each year in the United States. The disease is known as recurrent glioblastoma when the tumor progresses or recurs after initial treatment. Overall survival from the time of recurrence has been reported at 3-5 months without active treatment. The NovoTTF-100A System is a portable, non-invasive medical device designed for continuous use by patients. In vitro and in vivo studies have shown that the NovoTTF-100A System slows and reverses tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The NovoTTF-100A System creates a low intensity, alternating electric field within a tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death. In patients with recurrent glioblastoma brain tumors, the system has shown clinical efficacy comparable to that of active chemotherapies with better quality of life and without many of the side effects of chemotherapy. The NovoTTF-100A System has received marketing approval in the United States (U.S.) and is a CE Marked device cleared for sale in the European Union, Switzerland, Australia and Israel. NovoTTF Therapy is not approved for the treatment of non-small cell lung cancer in the United States. The safety and effectiveness of the therapy in this indication has not been established.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|